GT Biopharma (GTBP) EBITDA Margin (2010 - 2015)

GT Biopharma (GTBP) posted quarterly EBITDA Margin of 7155.0% for Q2 2015, up 72.34% quarter-over-quarter from 25871.43% in Q1 2015.

GT Biopharma (GTBP) EBITDA Margin (2010 - 2015) Analysis & Trends

GT Biopharma (GTBP) has reported EBITDA Margin for 5 consecutive years, with 7155.0% the latest figure, recorded in Q2 2015.

In Q2 2015, EBITDA Margin changed N/A year-over-year to 7155.0%; the TTM figure through Mar 2016 stood at 55085.0% (down 6974929.0% YoY), while the FY2015 annual figure was 33062.96%, down 2450582.0% from the prior year.
EBITDA Margin advanced to 7155.0% in Q2 2015 per GTBP's latest filing, from 25871.43% in the prior quarter.
Across five years, EBITDA Margin topped out at 600.81% in Q4 2012 and bottomed at 103000.0% in Q2 2012.
Historically, EBITDA Margin has averaged 26901.66% across 4 years, with a median of 25871.43% in 2015.
Annual changes were most pronounced in 2012 — EBITDA Margin tumbled 5490000 bps — and 2013, when it jumped 3920568 bps.
GT Biopharma's EBITDA Margin stood at 34933.33% in 2011, then soared by 102 bps to 600.81% in 2012, then slumped by 166 bps to 394.32% in 2013, then sank by 1715 bps to 7155.0% in 2015.
Business Quant data shows GTBP's EBITDA Margin at 7155.0% in Q2 2015, 25871.43% in Q1 2015, and 394.32% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	GT Biopharma	8.38 Mn	8.38 Mn	-	-

Download Data